Efficacy and Potential Limitation of the Menin Inhibitor Revumenib Outside Clinical Trials: Extramedullary Response with Central Nervous System Escape in a Case of KMT2A-Rearranged Acute Myeloid Leukemia
Acute myeloid leukemia (AML) harboring KMT2A rearrangements (KMT2A-r) accounts for approximately 5–10% of newly diagnosed cases and represents a high-risk AML subtype associated with poor clinical outcomes despite intensive treatment strategies, including allogeneic hematopoietic stem cell transplantation (HSCT). KMT2A...